The Government today said as many as 294 micro and small pharmaceuticals companies have availed of a subsidy of nearly Rs 19.76 crore for technology upgradation under the credit linked capital subsidy scheme (CLCSS).
"Under this scheme 294 drugs and pharmaceuticals micro and small enterprises have availed subsidy of about Rs 19.76 crore since inception of the CLCSS up to March, 2012," Minister of State for Chemical and Fertilisers Srikant Kumar Jena said in a written reply to the Lok Sabha.
He said said the Ministry of Micro, Small and Medium Enterprises is implementing the CLCSS to provide incentives to micro and small enterprises including drug and pharmaceuticals for technology upgradation.
"Under this scheme 15% capital subsidy is provided up to a loan of Rs 1 crore as per the guidelines of the scheme," Jena said.
The policy is being implemented for 48 sub-sectors including the drugs and pharmaceuticals sub-sector, he added.
In reply to a question, the Minister said upgradation helps companies to improve their quality standards though it may not necessarily bring down the prices.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
